

World Journal of *Clinical Oncology*

World J Clin Oncol 2017 August 10; 8(4): 305-377



**REVIEW**

- 305 Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know
Couñago F, Sancho G, Catalá V, Hernández D, Recio M, Montemuiño S, Hernández JA, Maldonado A, del Cerro E

MINIREVIEWS

- 320 Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
Tibaldi C, Lunghi A, Baldini E
- 329 Platinum-induced neurotoxicity: A review of possible mechanisms
Kanat O, Ertas H, Caner B

ORIGINAL ARTICLE**Retrospective Study**

- 336 Physician approaches to drug shortages: Results of a national survey of pediatric hematologist/oncologists
Beck JC, Chen B, Gordon BG
- 343 Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients
Gruber-Rouh T, Langenbach M, Naguib NNN, Nour-Eldin NEM, Vogl TJ, Zangos S, Beeres M

Observational Study

- 351 Rescue associating liver partition and portal vein ligation for staged hepatectomy after portal embolization: Our experience and literature review
Maulat C, Philis A, Charriere B, Mokrane FZ, Guimbaud R, Otaï P, Suc B, Muscari F

CASE REPORT

- 360 *BRAF* V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis
Qasrawi A, Tolentino A, Abu Ghanimeh M, Abughanimeh O, Albadarin S
- 366 Intimal sarcoma of the pulmonary artery with multiple lung metastases: Long-term survival case
García-Cabezas S, Centeno-Haro M, Espejo-Pérez S, Carmona-Asenjo E, Moreno-Vega AL, Ortega-Salas R, Palacios-Eito A
- 371 Long-term stabilization of metastatic melanoma with sodium dichloroacetate
Khan A, Andrews D, Shainhouse J, Blackburn AC

Contents

World Journal of Clinical Oncology
Volume 8 Number 4 August 10, 2017

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Oncology*, Che-Chun Su, MD, PhD, Associate Professor, Attending Doctor, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan

AIM AND SCOPE

World Journal of Clinical Oncology (*World J Clin Oncol*, *WJCO*, online ISSN 2218-4333, DOI: 10.5306) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJCO covers a variety of clinical medical topics, including etiology, epidemiology, evidence-based medicine, informatics, diagnostic imaging, endoscopy, tumor recurrence and metastasis, tumor stem cells, radiotherapy, chemotherapy, interventional radiology, palliative therapy, clinical chemotherapy, biological therapy, minimally invasive therapy, physiotherapy, psycho-oncology, comprehensive therapy, and oncology-related nursing. Priority publication will be given to articles concerning diagnosis and treatment of oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJCO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING

World Journal of Clinical Oncology is now indexed in PubMed, PubMed Central and Scopus.

FLYLEAF

I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*
Proofing Editorial Office Director: *Ze-Mao Gong*

NAME OF JOURNAL
World Journal of Clinical Oncology

ISSN
ISSN 2218-4333 (online)

LAUNCH DATE
November 10, 2010

FREQUENCY
Bimonthly

EDITOR-IN-CHIEF
Godefridus J Peters, PhD, Professor, Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam 1081 HV, Netherlands

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/2218-4333/editorialboard.htm>

EDITORIAL OFFICE
Xiu-Xia Song, Director

World Journal of Clinical Oncology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive,
Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
August 10, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION

<http://www.f6publishing.com>

Platinum-induced neurotoxicity: A review of possible mechanisms

Ozkan Kanat, Hulya Ertas, Burcu Caner

Ozkan Kanat, Hulya Ertas, Burcu Caner, Department of Medical Oncology, Uludag University Faculty of Medicine, 16059 Bursa, Turkey

Author contributions: Kanat O assigned the issue and performed the majority of the writing, prepared the figure; Ertas H and Caner B both designed the outline and coordinated the writing of the manuscript.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Uludag University Faculty of Medicine, Gorukle, 16059 Bursa, Turkey. ozkanat@uludag.edu.tr
Telephone: +90-224-2951321

Received: April 10, 2017

Peer-review started: April 12, 2017

First decision: May 22, 2017

Revised: June 13, 2017

Accepted: June 30, 2017

Article in press: July 3, 2017

Published online: August 10, 2017

discontinuation of platinum drugs, these symptoms can persist over a long period of time. Cisplatin and oxaliplatin, among all platinum drugs, have significant neurotoxic potential. A distal dose-dependent symmetrical sensory neuropathy is the most common presentation of platinum neurotoxicity. DNA damage-induced apoptosis of dorsal root ganglion (DRG) neurons seems to be the principal cause of neurological symptoms. However, DRG injury alone cannot explain some unique symptoms such as cold-aggravated burning pain affecting distal extremities that is observed with oxaliplatin administration. In this article, we briefly reviewed potential mechanisms for the development of platinum drugs-associated neurological manifestations.

Key words: Cisplatin; Dorsal root ganglion; Mechanism; Oxaliplatin; Neurotoxicity; Neuropathic pain; Sodium channel

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Platinum drug-based chemotherapies may lead to intolerable neuropathic symptoms, preventing their administration at the optimal effective doses and duration. A better understanding of potential mechanisms underlying these symptoms can help clinicians better manage patients experiencing acute and/or cumulative neurotoxicity during treatment with platinum-containing chemotherapy.

Kanat O, Ertas H, Caner B. Platinum-induced neurotoxicity: A review of possible mechanisms. *World J Clin Oncol* 2017; 8(4): 329-335 Available from: URL: <http://www.wjgnet.com/2218-4333/full/v8/i4/329.htm> DOI: <http://dx.doi.org/10.5306/wjco.v8.i4.329>

Abstract

Patients treated with platinum-based chemotherapy frequently experience neurotoxic symptoms, which may lead to premature discontinuation of therapy. Despite

INTRODUCTION

Platinum drugs, including cisplatin (cis-diamminedi-

chloroplatinum II), carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II), and oxaliplatin (trans-R,R-cyclohexane-1,2-diamineoxalatoplatinum II) have become an important part of the combination chemotherapy regimens used to treat different types of solid tumors. Despite their favorable anti-tumor properties, platinum drugs can cause serious side effects such as neurotoxicity^[1-3].

Carboplatin neurotoxicity is negligible compared with that of cisplatin and oxaliplatin, however, it can develop, particularly high doses are administered^[3,4]. Exposure of rat sensory neurons in culture to cisplatin, oxaliplatin or carboplatin *in vitro* caused a concentration-dependent increase in cell death and apoptotic cells^[5]. However, carboplatin required a 10-fold higher drug concentration than cisplatin to induce a similar degree of cytotoxic effect. In addition, both cisplatin and oxaliplatin led to increased reactive oxygen species production and 8-oxoguanine DNA damage, but carboplatin did not^[5]. These preclinical observations may partly explain why carboplatin has less neurotoxic effects.

Conversely, conventional-dose cisplatin- or oxaliplatin-based therapies can sometimes lead to intolerable neuropathic symptoms, preventing their administration at the optimal effective doses and duration. Large-diameter sensory nerve fibers appear to be the most affected by platinum drugs, leading to symmetrical glove and stocking type of sensory loss, numbness, tingling, pain, and burning sensation^[4]. Some of these symptoms may persist for months or even years. Furthermore, in some cases, they may continue to worsen even after treatment cessation, a phenomenon known as "coasting"^[6].

Platinum-induced neurologic symptoms become evident when certain cumulative drug doses have been administered. Cumulative doses of cisplatin and oxaliplatin of 350 mg/m² and 550 mg/m², respectively, have been considered as the threshold values for neurotoxicity development^[6]. Some clinical and genetic features of patients may make them more susceptible to developing severe neurotoxicity during treatment with platinum drugs. A recent study by Velasco *et al.*^[7] found that among patients treated with oxaliplatin-based chemotherapy, male patients, patients experiencing more severe acute neuropathic symptoms, patients with abnormal findings on mid-treatment nerve conduction velocity studies, and patients receiving higher cumulative oxaliplatin doses have an increased risk of developing significant neuropathic symptoms. Several recent pharmacogenomics studies have suggested that patients with polymorphisms in the Glutathione S-transferases genes (GSTM1, GSTT1, and GSTP1) are more likely to develop grade 3-4 cumulative neuropathy during oxaliplatin treatment due to decreased drug detoxification^[8].

Oxaliplatin may also cause acute dose-independent neurotoxicity, which can occur in approximately 90% of patients during or shortly after infusion, and is characterized by transient cold-induced paresthesias

and dysesthesias affecting the distal extremities, and perioral and pharyngolaryngeal regions^[9,10].

A better understanding of the potential mechanisms underlying cisplatin or oxaliplatin neurotoxicity will certainly help clinicians identify the optimal clinical management of this side effect. The aim of this review was, therefore, to summarize the current knowledge on the neuronal events induced during platinum-based therapy.

Nuclear DNA damage in dorsal root ganglion neurons

The accumulation of platinum compounds and their metabolites in the dorsal root ganglion (DRG) after their systemic administration and formation of platinum-DNA adducts are considered key steps in neurotoxicity development (Figure 1)^[2,11]. The presence of an abundant fenestrated capillary network and the absence of blood-brain barrier in DRG allow platinum drugs to preferentially accumulate in DRG with easy access to sensory neurons^[2,11,12].

Recently, it was demonstrated that the uptake of platinum drugs into DRG neurons may be facilitated by two different types of neuronal membrane transporters: Copper transporter-1 (CTR1) and organic cation transporter-2 (OCT2)^[13-15]. The overexpression of these transporters in neurons, therefore, can contribute to the development or aggravation of neurotoxicity. For example, a 16- to 35-fold increase in the cellular oxaliplatin uptake was observed in neurons overexpressing mouse OCT2 or human OCT2, and this process resulted in significantly increased DNA platination and neurotoxicity^[15].

Once the platinum drugs reach the neuronal cell nucleus, they attack the nuclear DNA to form adducts. They usually form same types of adducts on the same DNA sites, including 1,2-intrastrand d (GpG) (between adjacent guanine bases on the same DNA strand) and 1,2-intrastrand d (ApG) (between adenine and adjacent guanine bases on the same DNA strand) crosslinks. A correlation between adduct levels and the degree of neurotoxicity has been reported^[16]. The platinum-DNA adduct levels produced by cisplatin were found to be approximately three times higher than those generated by equimolar oxaliplatin doses. Concordantly, *in vitro* cisplatin caused significantly more neuronal cell death than oxaliplatin^[16]. DNA repair ability of DRG neurons for adducts (primarily performed by the nucleoid excision repair) is an important factor determining neurotoxicity severity^[17]. Chronic cisplatin administration resulted in an accelerated accumulation of unrepaired platinum-DNA adducts in DRG neurons of DNA repair-deficient mice, which induced early neurophysiological alterations and led to an increase in neuronal cell death^[17].

Inhibition of the global transcriptional activity of DRG neurons is one of the major consequences of DNA adduct formation^[18]. DRG neurons need a high level of active transcription to sustain their large size, high metabolism, and long axons. Therefore, platinum-induced DNA damage leads to neuronal atrophy and disruption of their distant axonal connections^[18].




Figure 1 Proposed mechanisms of platinum-induced neurotoxicity. Dorsal root ganglion (DRG) is the main target of platinum drugs that preferentially accumulate in DRG neurons. Membrane transporters, copper transporter-1 (CTR1) and organic cation transporter-2 (OCT2), can facilitate the cellular uptake of platinum drugs. Platinum-DNA adducts inhibit replication and transcription, which results in caspase activation and subsequent cell death. Neuronal mitochondrial damage leads to cellular ATP depletion and increased reactive oxygen species (ROS) production. The voltage-gated sodium (Na⁺), potassium (K⁺) and calcium (Ca²⁺) channels dysfunction, and the enhanced expression and responsiveness of transient receptor potential channels (TRPA1, transient receptor potential ankyrin-1; TRPM8, transient receptor potential melastatin 8; TRPV1, transient receptor potential vanilloid 1) play an important role in the development of platinum-induced neurotoxicity.

Several preclinical studies have reported that platinum-induced DNA damage also induces apoptosis and neuron loss in DRG both *in vivo* and *in vitro*^[19-22]. Cisplatin has been shown to initiate several apoptotic events in neuronal cells, including p53 activation, Bax translocation, mitochondrial cytochrome c release, and activation of caspase-3 and caspase-9. Gill and Windebank demonstrated that following exposure to cisplatin, DRG neurons attempt to re-enter the cell cycle from G0 phase, and this event can be a prelude to triggering neuronal cell death^[22].

Mitochondrial DNA damage

Mitochondrial dysfunction in DRG neurons was first described as a potential mechanism for platinum drugs neurotoxicity by Podratz *et al.*^[23]. They demonstrated that cisplatin also directly binds to mitochondrial DNA with similar binding affinity as nuclear DNA. Cisplatin-mitochondrial DNA adducts inhibit mitochondrial DNA transcription and replication, and cause morphological changes in the mitochondria. This can lead to disruption of the electron transport chain, loss of adenosine triphosphate (ATP) generation, energy failure, and overproduction of reactive oxygen species. All these events cause the opening of mitochondrial permeability transition pores, mitochondrial membrane depolarization, intracellular calcium accumulation, and expression of apoptotic proteins.

Cisplatin may also impair mitochondrial transport dynamics in neurons^[24]. Proper mitochondrial transport in neurons is critical to cellular homeostasis. A new

study in *Drosophila* has shown that cisplatin can significantly reduce mitochondrial movement frequency in axons^[24]. This is probably caused by both ATP depletion and cellular calcium accumulation.

Some studies have demonstrated that cisplatin can alter the expression of mitochondrial fusion and fission proteins in peripheral nerves^[25]. These proteins regulate mitochondrial shape, size, and number. Bobylev *et al.*^[25] detected a significant decrease in the mitochondrial fusion protein mitofusin 2 expression levels in DRG and tibial nerves of cisplatin-treated mice, resulting in mitochondrial swelling and vacuolization.

Voltage-gated ion channels dysfunction (channelopathies)

Oxaliplatin exhibits a tetrodotoxin-like inhibitory effect on the neuron voltage-gated sodium (Na⁺) channels^[26-30]. It remarkably slows their inactivation and reduces the peak Na⁺ current, leading to an increase in the duration of the relative refractory period of sensory neurons. Oxaliplatin may also affect the Na⁺ channels indirectly *via* the chelation of extracellular calcium ions by its metabolite oxalate (diaminocyclohexane-platinum-C2O4)^[26]. Because of Na⁺ channel dysfunction, sensory neurons become hyperexcitable and eventually generate spontaneous ectopic discharges.

Oxaliplatin can display isoform-specific effects on voltage-gated Na⁺ channels leading to the development of unique neuropathy symptoms such as cold-aggravated peripheral pain^[31,32]. It has been suggested that oxaliplatin-induced Nav1.6 dysfunction may play a

role in cold allodynia development^[33,34]. Cooling in the presence of oxaliplatin increased Nav1.6-mediated persistent and resurgent Na⁺ currents in large-diameter DRG neurons and resulted in the generation of action potential burst firing^[31].

Peripheral nerve axonal excitability studies performed before and immediately after oxaliplatin administration have confirmed the above mentioned *in vitro* findings and revealed acute abnormalities in sensory nerve function related to Na⁺ channel dysfunction, including decreased refractoriness and increased superexcitability^[35]. Interestingly, it was shown that these excitability abnormalities can be detected in the initial oxaliplatin treatment cycles and may serve as a predictive tool to identify patients who are more likely to develop moderate or severe neurotoxicity.

Kagiava *et al.*^[33] suggested that altered voltage-gated potassium channel activity may be involved in oxaliplatin-induced neurotoxicity development. In their study, the effects of oxaliplatin on the compound action potential of rat sciatic nerve were observed to be similar to those with the potassium channel blockers 4-aminopyridine and tetraethylammonium. Oxaliplatin was found to cause broadening of action potentials and repetitive firing, suggesting its antagonistic effect on neuronal fast and slow potassium channels. This finding is indirectly supported by Sittl *et al.*^[34]. They showed that enhancement of axonal potassium conductance by flupirtine may reduce oxaliplatin-induced peripheral nerve hyperexcitability.

Conversely, voltage-gated potassium channels are unlikely to be the primary target for oxaliplatin because patch-clamp studies failed to show any effect of oxaliplatin on Shaker-type potassium channels^[36]. Kagiava *et al.*^[37] found some evidence indicating that potassium channel dysfunction during oxaliplatin treatment can occur due to malfunction of the gap junction (GJ) channels and hemichannels in myelinated fibers. According to their findings, oxaliplatin causes prolonged opening of GJ channels and hemichannels, leading to excessive potassium accumulation in the periaxonal space and its osmotic swelling. This event is likely to have a disturbing effect on the voltage-gated potassium channel function.

Cisplatin does not appear to have a prominent effect on the neuronal sodium or potassium channel function. Initial studies using whole cell patch-clamp electrophysiological technique reported that cisplatin decreases the calcium channel currents, particularly in small-diameter neurons of rat DRG^[38]. However, a new study revealed an increase in calcium influx through N-type calcium channels in rat DRG neurons after exposure to cisplatin^[39]. This was mainly caused by the upregulation of the N-type calcium channels. Increased intracellular calcium levels led to caspase-3 activation and apoptosis induction.

Enhanced responsiveness of thermosensitive transient receptor potential ion channels

Sensory neurons express various types of transient

receptor potential (TRP) channels, including TRPA1, TRPM8, and TRPV1, which all play an important role in the generation and sensation of inflammatory and neuropathic pain^[40-45].

Nassini *et al.*^[40] showed that oxaliplatin- and cisplatin-induced mechanical and cold hyperalgesia in rats are mediated by transient receptor potential ankyrin-1 (TRPA1), and TRPA1 activation is most likely caused by glutathione-sensitive molecules. Subsequently, Zhao *et al.*^[44] reported that oxaliplatin-induced cold hyperalgesia could be related to increased responsiveness of TRPA1. Pretreatment of the cultured DRG neurons with oxaliplatin resulted in an increase in the number of allyl-isothiocyanate (a TRPA1 agonist)-sensitive neurons.

The results of a recent study suggested that aluminum accumulation in DRG may augment oxaliplatin-induced neuropathic pain through activation of TRPA1 and stimulation of apoptotic cell death^[46]. In this study, aluminum concentration of in DRG was greater in mice treated with aluminum chloride and oxaliplatin than in those treated with aluminum chloride alone.

Gauchan *et al.*^[43] revealed that oxaliplatin treatment increased the cold receptor transient receptor potential melastatin 8 (TRPM8) expression in rat DRG neurons, which resulted in enhanced sensitivity to cooling stimulation. Capsazepine, a blocker of both TRPM8 and TRPV1 channels, but not the selective TRPV1 blocker 5'-Iodoresiniferatoxin, was able to inhibit oxaliplatin-induced cold allodynia. These findings suggested that TRPM8 plays a role in cold allodynia caused by oxaliplatin.

Ta *et al.*^[41] showed that mice DRG neurons treated with cisplatin or oxaliplatin displayed an increase in transient receptor potential vanilloid 1 (TRPV1), TRPA1, and TRPM8 mRNA expression. Trigeminal ganglion neurons from the cisplatin-treated animals showed increased TRPV1 and TRPA1 mRNA expression, and this was associated with enhanced heat and mechanical hypersensitivity. Conversely, oxaliplatin affected only TRPA1 expression, which induced cold and mechanosensitivity.

Glial activation

Di Cesare Mannelli *et al.*^[47,48] first suggested a link between oxaliplatin-induced neuropathic pain and glial activation. In a rat model with oxaliplatin-induced peripheral neuropathy, they showed a transient activation of microglia and astrocytes in the spinal cord and supraspinal areas involved with pain modulation accompanied by a decrease in mechanical and thermal pain thresholds following intraperitoneal oxaliplatin administration^[48]. Intrathecal co-administration of microglial inhibitor minocycline was able to prevent microglial activation, but had no effect on the response of astrocytes. The astrocytic activation could be inhibited by intrathecal injection of fluorocitrate, an astrocyte specific metabolic inhibitor. Fluorocitrate did not influence oxaliplatin-induced microglial activation. Both drugs increased pain tolerance, but fluorocitrate produced greater pain relief than minocycline. However, neither minocycline nor fluorocitrate prevented oxaliplatin-

dependent morphological alterations in DRG neurons^[48]. These findings provide some evidence for the participation of glial cells in oxaliplatin-induced neuropathy.

Involvement of nicotinic receptors

Oxaliplatin treatment was found to induce down regulation of alpha7 nicotinic acetylcholine receptor (nAChR) in the rat sciatic nerve, DRG, and spinal cord^[49]. The administration of the selective alpha7 nAChR agonists (R)-ICH3 and PNU-282987 could prevent receptor down regulation and increase the pain threshold by oxaliplatin. These two agonists also could inhibit oxaliplatin-induced morphological changes in DRG and peripheral nerves, and upregulate glial cell density in the spinal cord, thalamus, and somatosensory area 1. CDP-choline, the other selective alpha7 nAChR agonist, was also found to be effective in reducing oxaliplatin-induced mechanical hyperalgesia when administered into the cerebral ventricles^[50]. These findings suggested a neuroprotective role of alpha7 nAChR during oxaliplatin treatment.

DETECTION AND ASSESSMENT OF PLATINUM-INDUCED NEUROTOXICITY

Currently, no standard clinical method for the early detection and comprehensive assessment of platinum-induced neurotoxicity is known. The use of self-reporting questionnaires developed by the United States National Cancer Institute and European Organization for Research and Treatment of Cancer throughout the treatment course has been recommended as a simple clinical tool for determining and grading a pre-existing or new neuropathy^[51,52]. These questionnaires contain items that evaluate the occurrence, severity, degree of distress, and frequency of neuropathic symptoms and their negative impacts on the patient daily activities.

Among neurophysiological techniques, nerve conduction velocity studies and electromyography remain the gold standard technique for detecting the location and extent of neuronal damage due to treatment with platinum drugs^[1,6]. Nerve excitability studies performed before and immediately after oxaliplatin infusion have emerged as novel non-invasive tests for early identification of patients at high risk for severe neurotoxicity^[35,53].

PREVENTION AND TREATMENT STRATEGIES

A recent Cochrane review examined the effects of the potential chemo-protective agents against neurotoxicity of platinum analogs^[54]. This review included 29 randomized controlled trials (RCTs) and analyzed data from 2906 participants who received platinum-containing chemotherapy (cisplatin, carboplatin, or oxaliplatin) alone or in combination with a potential chemo-protectant, including amifostine, calcium/magnesium infusion, glutathione, Org 2766, acetylcysteine, oxcarbazepine, or

vitamin E^[54]. The data obtained in this study were found to be insufficient to recommend any particular agent to prevent or limit platinum drug neurotoxicity.

In 2014, the American Society of Clinical Oncology convened an expert panel to develop a clinical practice guideline for the prevention and treatment of chemotherapy-induced neuropathies in adult cancer survivors^[55]. The experts reviewed 48 RCTs that investigated the efficacy of pharmacological agents, including antiepileptic drugs (carbamazepine and oxcarbazepine), antidepressants (amitriptyline, nortriptyline, venlafaxine and duloxetine), vitamins/minerals (calcium/magnesium infusions, vitamin E, and glutamine), and antioxidants (glutathione, N-acetylcysteine, and amifostine) against neuropathic pain caused by platinum compounds, paclitaxel or vinca alkaloids. They concluded that enough evidence to support routine clinical implementation of these agents for the prevention of platinum-induced peripheral neurotoxicity was not found. Conversely, duloxetine was found potentially useful for treating oxaliplatin-induced neuropathic pain.

CONCLUSION

The apoptotic loss of DRG neurons plays a central role in the initiation and progression of platinum-induced neurotoxicity. Recent evidence suggests that secondary mitochondrial dysfunction can mediate and aggravate cisplatin-mediated neuronal damage. Impaired activity of voltage-gated ion channels and/or increased sensitivity of TRP channels in sensory neurons seem to be the major events leading to the development of oxaliplatin-induced acute neurological side effects, including cold-induced paresthesias and painful dysesthesias. The potential roles of glial cells and nAChRs in platinum-induced neurotoxicity deserve further investigation to explore new strategies to prevent and to treat this side effect.

REFERENCES

1. **Avan A**, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, Peters GJ. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. *Oncologist* 2015; **20**: 411-432 [PMID: 25765877]
2. **Carozzi VA**, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? *Neurosci Lett* 2015; **596**: 90-107 [PMID: 25459280]
3. **Amptoulach S**, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. *Chemother Res Pract* 2011; **2011**: 843019 [PMID: 22312559 DOI: 10.1155/2011/843019]
4. **Chiorazzi A**, Semperboni S, Marmioli P. Current view in platinum drug mechanisms of peripheral neurotoxicity. *Toxics* 2015; **3**: 304-321 [DOI: 10.3390/toxics3030304]
5. **Kelley MR**, Jiang Y, Guo C, Reed A, Meng H, Vasko MR. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. *PLoS One* 2014; **9**: e106485 [PMID: 25188410 DOI: 10.1371/journal.pone.0106485]
6. **Park SB**, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. *CA Cancer J Clin* 2013; **63**: 419-437 [PMID: 24590861 DOI: 10.3322/caac.21204]

- 7 **Velasco R**, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, Frigeni B, Cacciavillani M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. *J Neurol Neurosurg Psychiatry* 2014; **85**: 392-398 [PMID: 23813745 DOI: 10.1136/jnnp-2013-305334]
- 8 **Cavaletti G**, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. *Lancet Oncol* 2011; **12**: 1151-1161 [PMID: 21719347 DOI: 10.1016/S1470-2045(11)70131-0]
- 9 **Pasetto LM**, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? *Crit Rev Oncol Hematol* 2006; **59**: 159-168 [PMID: 16806962]
- 10 **Lucchetta M**, Lonardi S, Bergamo F, Alberti P, Velasco R, Argyriou AA, Briani C, Bruna J, Cazzaniga M, Cortinovis D, Cavaletti G, Kalofonos HP. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. *Cancer Chemother Pharmacol* 2012; **70**: 899-902 [PMID: 23108696 DOI: 10.1007/s00280-012-2006-8]
- 11 **McWhinney SR**, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. *Mol Cancer Ther* 2009; **8**: 10-16 [PMID: 19139108 DOI: 10.1158/1535-7163.MCT-08-0840]
- 12 **Jimenez-Andrade JM**, Herrera MB, Ghilardi JR, Vardanyan M, Melemedjian OK, Mantyh PW. Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. *Mol Pain* 2008; **4**: 10 [PMID: 18353190 DOI: 10.1186/1744-8069-4-10]
- 13 **Cavaletti G**, Ceresa C, Nicolini G, Marmiroli P. Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity. *Anticancer Res* 2014; **34**: 483-486 [PMID: 24403505]
- 14 **Ciarimboli G**. Membrane transporters as mediators of Cisplatin effects and side effects. *Scientifica* (Cairo) 2012; **2012**: 473829 [PMID: 24278698 DOI: 10.6064/2012/473829]
- 15 **Sprowl JA**, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. *Proc Natl Acad Sci USA* 2013; **110**: 11199-11204 [PMID: 23776246 DOI: 10.1073/pnas.1305321110]
- 16 **Ta LE**, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. *Neurotoxicology* 2006; **27**: 992-1002 [PMID: 16797073]
- 17 **Dzagnidze A**, Katsarava Z, Makhalova J, Liedert B, Yoon MS, Kaube H, Limmroth V, Thomale J. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. *J Neurosci* 2007; **27**: 9451-9457 [PMID: 17728458]
- 18 **Yan F**, Liu JJ, Ip V, Jamieson SM, McKeage MJ. Role of platinum DNA damage-induced transcriptional inhibition in chemotherapy-induced neuronal atrophy and peripheral neurotoxicity. *J Neurochem* 2015; **135**: 1099-1112 [PMID: 26364854 DOI: 10.1111/jnc.13355]
- 19 **McDonald ES**, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. *Neurobiol Dis* 2005; **18**: 305-313 [PMID: 15686959]
- 20 **Alaedini A**, Xiang Z, Kim H, Sung YJ, Latov N. Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. *Exp Neurol* 2008; **210**: 368-374 [PMID: 18191839 DOI: 10.1016/j.expneurol.2007.11.018]
- 21 **Cavaletti G**, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne GG. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. *Eur J Cancer* 2001; **37**: 2457-2463 [PMID: 11720843]
- 22 **Gill JS**, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. *J Clin Invest* 1998; **101**: 2842-2850 [PMID: 9637718 DOI: 10.1172/JCI1130]
- 23 **Podratz JL**, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, Schlattau A, Lathroum L, Windebank AJ. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. *Neurobiol Dis* 2011; **41**: 661-668 [PMID: 21145397 DOI: 10.1016/j.nbd.2010.11.017]
- 24 **Podratz JL**, Lee H, Knorr P, Koehler S, Forsythe S, Lambrecht K, Arias S, Schmidt K, Steinhoff G, Yudinsev G, Yang A, Trushina E, Windebank A. Cisplatin induces mitochondrial deficits in *Drosophila* larval segmental nerve. *Neurobiol Dis* 2017; **97**: 60-69 [PMID: 27765583 DOI: 10.1016/j.nbd.2016.10.003]
- 25 **Bobylev I**, Joshi AR, Barham M, Neiss WF, Lehmann HC. Depletion of Mitofusin-2 Causes Mitochondrial Damage in Cisplatin-Induced Neuropathy. *Mol Neurobiol* 2017 Jan 21; Epub ahead of print [PMID: 28110471 DOI: 10.1007/s12035-016-0364-7]
- 26 **Adelsberger H**, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. *Eur J Pharmacol* 2000; **406**: 25-32 [PMID: 11011028]
- 27 **Park SB**, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Dose effects of oxaliplatin on persistent and transient Na⁺ conductances and the development of neurotoxicity. *PLoS One* 2011; **6**: e18469 [PMID: 21494615 DOI: 10.1371/journal.pone.0018469]
- 28 **Krishnan AV**, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin and axonal Na⁺ channel function in vivo. *Clin Cancer Res* 2006; **12**: 4481-4484 [PMID: 16899592]
- 29 **Wu SN**, Chen BS, Wu YH, Peng H, Chen LT. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. *Neurotoxicology* 2009; **30**: 677-685 [PMID: 19422847 DOI: 10.1016/j.neuro.2009.04.010]
- 30 **Webster RG**, Brain KL, Wilson RH, Grem JL, Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. *Br J Pharmacol* 2005; **146**: 1027-1039 [PMID: 16231011]
- 31 **Sittl R**, Lampert A, Huth T, Schuy ET, Link AS, Fleckenstein J, Alzheimer C, Grafe P, Carr RW. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. *Proc Natl Acad Sci USA* 2012; **109**: 6704-6709 [PMID: 22493249 DOI: 10.1073/pnas.1118058109]
- 32 **Deuis JR**, Zimmermann K, Romanovsky AA, Possani LD, Cabot PJ, Lewis RJ, Vetter I. An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. *Pain* 2013; **154**: 1749-1757 [PMID: 23711479 DOI: 10.1016/j.pain.2013.05.032]
- 33 **Kagiava A**, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. *Neurotoxicology* 2008; **29**: 1100-1106 [PMID: 18845186 DOI: 10.1016/j.neuro.2008.09.005]
- 34 **Sittl R**, Carr RW, Fleckenstein J, Grafe P. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. *Neurotoxicology* 2010; **31**: 694-700 [PMID: 20670646 DOI: 10.1016/j.neuro.2010.07.006]
- 35 **Park SB**, Lin CS, Kiernan MC. Nerve excitability assessment in chemotherapy-induced neurotoxicity. *J Vis Exp* 2012; **(62)**: 3439 [PMID: 22565594 DOI: 10.3791/3439]
- 36 **Broomand A**, Jerremalm E, Yachnin J, Ehrsson H, Elinder F. Oxaliplatin neurotoxicity--no general ion channel surface-charge effect. *J Negat Results Biomed* 2009; **8**: 2 [PMID: 19138416 DOI: 10.1186/1477-5751-8-2]
- 37 **Kagiava A**, Theophilidis G, Sargiannidou I, Kyriacou K, Kleopa KA. Oxaliplatin-induced neurotoxicity is mediated through gap junction channels and hemichannels and can be prevented by octanol. *Neuropharmacology* 2015; **97**: 289-305 [PMID: 26044641 DOI: 10.1016/j.neuropharm.2015.05.021]
- 38 **Tomaszewski A**, Büsselberg D. Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. *Neurotoxicology* 2007; **28**: 49-58 [PMID: 16945417]
- 39 **Leo M**, Schmitt LI, Erkel M, Melnikova M, Thomale J, Hagenacker T. Cisplatin-induced neuropathic pain is mediated by upregulation of N-type voltage-gated calcium channels in dorsal root ganglion neurons. *Exp Neurol* 2017; **288**: 62-74 [PMID: 27823926 DOI: 10.1016/j.expneurol.2016.11.003]
- 40 **Nassini R**, Gees M, Harrison S, De Siena G, Materazzi S, Moretto

- N, Failli P, Preti D, Marchetti N, Cavazzini A, Mancini F, Pedretti P, Nilius B, Patacchini R, Geppetti P. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. *Pain* 2011; **152**: 1621-1631 [PMID: 21481532 DOI: 10.1016/j.pain.2011.02.051]
- 41 **Ta LE**, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. *Mol Pain* 2010; **6**: 15 [PMID: 20205720 DOI: 10.1186/1744-8069-6-15]
- 42 **Kono T**, Satomi M, Suno M, Kimura N, Yamazaki H, Furukawa H, Matsubara K. Oxaliplatin-induced neurotoxicity involves TRPM8 in the mechanism of acute hypersensitivity to cold sensation. *Brain Behav* 2012; **2**: 68-73 [PMID: 22574275 DOI: 10.1002/brb3.34]
- 43 **Gauchan P**, Andoh T, Kato A, Kuraishi Y. Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. *Neurosci Lett* 2009; **458**: 93-95 [PMID: 19375484 DOI: 10.1016/j.neulet.2009.04.029]
- 44 **Zhao M**, Isami K, Nakamura S, Shirakawa H, Nakagawa T, Kaneko S. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. *Mol Pain* 2012; **8**: 55 [PMID: 22839205 DOI: 10.1186/1744-8069-8-55]
- 45 **Nativi C**, Gualdani R, Dragoni E, Di Cesare Mannelli L, Sostegni S, Norcini M, Gabrielli G, la Marca G, Richichi B, Francesconi O, Moncelli MR, Ghelardini C, Roelens S. A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain. *Sci Rep* 2013; **3**: 2005 [PMID: 23774285 DOI: 10.1038/srep02005]
- 46 **Park JH**, Chae J, Roh K, Kil EJ, Lee M, Auh CK, Lee MA, Yeom CH, Lee S. Oxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root Ganglion Is Correlated with Aluminum Accumulation. *PLoS One* 2015; **10**: e0124875 [PMID: 25928068 DOI: 10.1371/journal.pone.0124875]
- 47 **Di Cesare Mannelli L**, Pacini A, Bonaccini L, Zanardelli M, Mello T, Ghelardini C. Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. *J Pain* 2013; **14**: 1585-1600 [PMID: 24135431 DOI: 10.1016/j.jpain.2013.08.002]
- 48 **Di Cesare Mannelli L**, Pacini A, Micheli L, Tani A, Zanardelli M, Ghelardini C. Glial role in oxaliplatin-induced neuropathic pain. *Exp Neurol* 2014; **261**: 22-33 [PMID: 24967684 DOI: 10.1016/j.expneurol.2014.06.016]
- 49 **Di Cesare Mannelli L**, Pacini A, Matera C, Zanardelli M, Mello T, De Amici M, Dallanocce C, Ghelardini C. Involvement of $\alpha 7$ nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. *Neuropharmacology* 2014; **79**: 37-48 [PMID: 24225197 DOI: 10.1016/j.neuropharm.2013.10.034]
- 50 **Kanat O**, Bagdas D, Ozboluk HY, Gurun MS. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. *J BUON* 2013; **18**: 1012-1018 [PMID: 24344031]
- 51 **Alberti P**, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G, CI-PeriNomS Group. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. *Ann Oncol* 2014; **25**: 257-264 [PMID: 24256846 DOI: 10.1093/annonc/mdt409]
- 52 **Curcio KR**. Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature. *Clin J Oncol Nurs* 2016; **20**: 144-151 [PMID: 26991707 DOI: 10.1188/16.CJON.20-01AP]
- 53 **Hill A**, Bergin P, Hanning F, Thompson P, Findlay M, Damianovich D, McKeage MJ. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. *BMC Cancer* 2010; **10**: 451 [PMID: 20731872 DOI: 10.1186/1471-2407-10-451]
- 54 **Albers JW**, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. *Cochrane Database Syst Rev* 2014; **(3)**: CD005228 [PMID: 24687190 DOI: 10.1002/14651858.CD005228]
- 55 **Hershman DL**, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2014; **32**: 1941-1967 [PMID: 24733808 DOI: 10.1200/JCO.2013.54.0914]

P- Reviewer: Chen CJ, Levine JD, Lotti M **S- Editor:** Ji FF
L- Editor: A **E- Editor:** Lu YJ





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

